Johnson & Johnson Halts DUPLEX-AD Atopic Dermatitis Study Early

In late December 2025, Johnson & Johnson announced the early termination of its Phase 2b proof-of-concept clinical study known as DUPLEX-AD, which was evaluating the investigational therapy JNJ-95475939 (also referred to as JNJ-5939) in patients with moderate to severe atopic dermatitis. The decision followed a planned interim efficacy analysis that did not meet the company’s predefined criteria for advancing this candidate in its atopic dermatitis clinical development program.

Study Objective and Outcome
The DUPLEX-AD trial was designed to assess whether JNJ-95475939 could provide a meaningful therapeutic benefit for individuals suffering from moderate to severe atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching, redness, and disrupted skin barriers. Atopic dermatitis affects tens of millions of people globally, and there remains a significant unmet need for treatments that provide sustained disease control with favorable safety profiles.

After conducting an interim analysis as stipulated in the study protocol, Johnson & Johnson determined that the results did not achieve the high-bar efficacy thresholds it had established for progressing further in this stage of clinical development. Although the therapy was reported to be generally well-tolerated by participants, the lack of sufficient efficacy led the company to discontinue the trial.

Implications for Competitive Positioning
Atopic dermatitis is an area with several competitive therapeutic options already approved, including biologics targeting key pathways in type 2 inflammation. Against this backdrop, Johnson & Johnson’s discontinuation of the DUPLEX-AD study underscores the challenges of differentiating new mechanisms of action in a crowded field with established treatments. The company’s evaluation criteria reflect not only regulatory expectations but also the need to demonstrate meaningful value over existing therapies to justify continued development and potential market adoption.

Future Development and Pipeline Focus
While the discontinuation marks a setback for JNJ-95475939 in atopic dermatitis, Johnson & Johnson emphasized its ongoing commitment to advancing its wider pipeline of clinical-stage and preclinical candidates aimed at addressing unmet needs in immunology. The company indicated it will continue to pursue new treatments that have the potential to transform care for individuals affected by chronic and debilitating conditions such as atopic dermatitis, while also balancing portfolio priorities in other therapeutic areas.

Forward-Looking Considerations
Johnson & Johnson’s statement on the DUPLEX-AD study included cautionary language regarding forward-looking statements, noting the inherent uncertainties in drug research and development, competitive pressures, and regulatory hurdles that may influence future outcomes. These factors are typical for clinical stage programs and reflect broader risks associated with advancing novel therapies through rigorous testing and approval processes.

www.jnj.com